Read More
Clinical Trials

Advancing novel candidates with the highest likelihood of driving significant benefit for patients.

We’re committed to evolving immunology. Our pipeline includes programs that are targeted to address highly prevalent chronic inflammatory diseases. Our goal is to develop therapeutics with profiles that will drive meaningful advances for patients with these diseases.

STUDY
TRIAL OVERVIEW
Program:
EVO756-CSU001
Indication:
Chronic Spontaneous Urticaria (CSU)
Status:
Phase 2b, Ongoing

EVO756-CSU001 is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study assessing EVO756, at multiple doses, in adults with chronic spontaneous urticaria. Participants will receive EVO756 or placebo daily for a 12-week treatment period and be evaluated for safety and efficacy at pre-specified visits at the clinical study site during the treatment period. Patients will return to the clinic for final assessments 2 weeks following the last dose of study drug.

For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT06873516.

Program:
EVO756-AD001
Indication:
Atopic Dermatitis
Status:
Phase 2b, Ongoing

EVO756-AD001 is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study assessing EVO756, at multiple doses, in adults with moderate to severe atopic dermatitis. Participants will receive EVO756 or placebo daily for a 12-week treatment period and be evaluated for safety and efficacy at pre-specified visits at the clinical study site during the treatment period. Participants will return to the clinic for a final assessments 2 weeks following the last dose of study drug.

For additional information about the trial, please visit clinilcatrials.gov using the identifier NCT07150845.

Program:
EVO301-AD001
Indication:
Atopic Dermatitis
Status:
Phase 2a, Ongoing

EVO301-AD001 is a Phase 2a, randomized, double-blind, placebo-controlled, multi-center study assessing EVO301 in adults with moderate to severe atopic dermatitis. Participants will be administered two intravenous treatments of EVO301 or placebo and be evaluated for safety and efficacy at pre-specified visits at the clinical study site during the 12-week study period.

For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT06723405.

Expanded Access Policy

Currently, Evommune’s investigational therapies are not available on an expanded access or right-to-try basis for new patients. In the event Evommune decides to consider expanded access or right-to-try use, Evommune will evaluate and respond to each request that it receives on a case-by-case basis. For more information on Evommune’s investigational therapies and ongoing clinical trials, please visit clinicaltrials.gov.

We are focused on novel therapies that target the drivers of chronic inflammatory disease.

See Our Approach